Wednesday, 22 January 2025
  
Login

Australia's most trusted
source of pharma news

Wednesday, 22 January 2025
News

Company cops a red-hot roasting

 Posted 21 January 2025 AM

A patient support program offering financial help to access fertility services has landed Vertex in hot water with the US Department of Health and Human Services (HHS) which has accused the company of attempting to violate anti-kickback laws.

A court case in the US District Court of Columbia has thrown the company's gene therapy Casgevy, for sickle cell disease and transfusion-dependent beta-thalassaemia into the spotlight for all the wrong reasons, and offers a masterclass into how a patient program, no matter how well-intentioned, can backfire.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (5)

Sales & Customer Relations (14)

Clinical & Medical, R&D (5)

Regulatory, Pharmacovigilance & QA (2)

Other (11)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.